Vitae Pharmaceuticals, Inc.
Records under this name other than the patents Vitae Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 44 patents it holds.
Back to Vitae Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,138,178 | Cyclic Inhibitors of 11BETA-HYDROXYSTEROID Dehydrogenase 1 Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,680,093 | Cyclic Inhibitors of 11BETA-HYDROXYSTEROID Dehydrogenase 1 Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,663,470 | Aryl- and Heteroarylcarbonyl Derivatives of Hexahydroindenopyridine and Octahydrobenzoquinoline Formerly held In force · High confidence | In force | High confidence | |
| US 9,090,605 | Substituted 5-,6- and 7-Membered Heterocycles, Medicaments Containing Such Compounds, and Their Use Formerly held In force · High confidence | In force | High confidence | |
| US 10,654,884 | Purine Derivatives as CD73 Inhibitors for the Treatment of Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 11,919,901 | Inhibitors of the Menin-Mll Interaction Formerly held In force · High confidence | In force | High confidence | |
| US 10,188,618 | Treatment of Cancer with Specific RXR Agonists Formerly held Term ended Term ended Oct 2, 2026 · Medium confidence | Term ended | Term ended Oct 2, 2026 | Medium confidence |
| US 10,596,133 | Treatment of cancer with specific RXR agonists Formerly held In force Ended no later than Oct 2, 2026 · From the USPTO record | In force | Ended no later than Oct 2, 2026 | From the USPTO record |
| US 10,973,788 | Treatment of cancer with specific RXR agonists Formerly held In force Ended no later than Oct 2, 2026 · From the USPTO record | In force | Ended no later than Oct 2, 2026 | From the USPTO record |
| US 10,047,085 | Dihydropyrrolopyridine Inhibitors of Ror-Gamma Lapsed on the fee record Ended Aug 14, 2026 · High confidence | Lapsed on the fee record | Ended Aug 14, 2026 | High confidence |